Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-01 Nasal Spray PK Study in Chinese Adults with Dry Eye Disease
NCT05576415Phase 1Completed
- Sponsor
- CORXEL Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of varenicline + nicotine patch in dry eye disease (DED), sponsored by CORXEL Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 28, Time to Maximum Plasma Concentration at Day 28 and 3 more. Started Dec 2022; status: completed.
02
Drugs
varenicline + nicotine patch
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05576415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576415.